Citadel Advisors
TRAW icon

Citadel Advisors’s Traws Pharma TRAW Stock Holding History

Citadel Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-104
Closed -$2.63K – 15613
2024
Q1 		$2.63K Buy
+104
New +$2K ﹤0.01% 13989
2023
Q1 		– Sell
-9,280
Closed -$149K – 15650
2022
Q4 		$149K Sell
9,280
-1,456
-14% -$27.5K ﹤0.01% 10615
2022
Q3 		$236K Sell
10,736
-5,152
-32% -$156K ﹤0.01% 10074
2022
Q2 		$524K Buy
+15,888
New +$536K ﹤0.01% 8541
2022
Q1 		– Sell
-1,264
Closed -$81K – 14748
2021
Q4 		$81K Buy
1,264
+720
+132% +$57.9K ﹤0.01% 12935
2021
Q3 		$52K Buy
+544
New +$70.1K ﹤0.01% 13356

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's TRAW Position: Q1 2026 in Review

Citadel Advisors sold out of Traws Pharma (TRAW) in Q1 2026, closing a stake of 24,819 shares — an estimated $28K sold.

Citadel Advisors first reported a position in TRAW in Q4 2015 and held it in 20 quarters. The position peaked at $270K in Q3 2021. 28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

  • Citadel Advisors reported no remaining Traws Pharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 24,819 Traws Pharma shares in Q1 2026, an estimated $28K.
  • Citadel Advisors first reported a position in Traws Pharma in Q4 2015 and held it in 20 quarters.
  • Citadel Advisors's Traws Pharma position peaked at $270K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.